Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16246252 | 0.87 | GSK3B (0.41) | GSK3BDYRK1AMAPKAPK2GRIN2BNAMPT | |
| SCHEMBL13323075 | 0.85 | GSK3B (0.41) | GSK3BDYRK1AMAPKAPK2GRIN2BNAMPT | |
| SCHEMBL27886524 | 0.84 | MAPKAPK2 (0.40) | GSK3BDYRK1AMAPKAPK2GRIN2BNAMPT | |
| SCHEMBL29934934 | 0.84 | GSK3B (0.40) | GSK3BDYRK1AMAPKAPK2GRIN2BNAMPT | |
| SCHEMBL2668927 | 0.84 | GSK3B (0.40) | GSK3BDYRK1AMAPKAPK2GRIN2BNAMPT | |
| SCHEMBL611654 | 0.84 | GSK3B (0.40) | GSK3BDYRK1AMAPKAPK2GRIN2BNAMPT | |
| SCHEMBL7452419 | 0.84 | MAPKAPK2 (0.42) | GSK3BDYRK1AMAPKAPK2GRIN2BNAMPT | |
| SCHEMBL19053692 | 0.83 | MAPKAPK2 (0.42) | GSK3BDYRK1AMAPKAPK2GRIN2BNAMPT | |
| SCHEMBL9897762 | 0.83 | GSK3B (0.40) | GSK3BDYRK1AMAPKAPK2GRIN2BNAMPT | |
| SCHEMBL2644186 | 0.82 | GSK3B (0.39) | GSK3BDYRK1AMAPKAPK2GRIN2BNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-8329707-B2 | Substituted pyrazine compounds | ASTELLAS PHARMA INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2236498-A1 | PHENYL ACETAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | AADAC, PGC, PC | GSK3B 3595/4885DYRK1A 3445/4885PTGDR2 461/4885 |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | PC, PCK2, GCKR | GSK3B 3415/4885DYRK1A 2612/4885PTGDR2 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.